UNDATED (AP) — New York-based Pfizer and BioNTech (byAHN’-tehk) of Germany have asked the U.S. Food and Drug Administration to expand the emergency use authorization for their vaccine to include adolescents ages 12 through 15. Back in mid-December, the two-dose shot received emergency clearance for vaccinating people ages 16 and up. Pfizer and BioNTech said they are working closely with the FDA and regulators in other countries to get emergency or conditional authorization as quickly as possible for kids ages 12 through 15.
Vaccine companies looking for wider emergency clearance
